MIAMI, Aug. 29, 2007 (PRIME NEWSWIRE) -- Galea Life Sciences, Inc. (Pink Sheets:GLSN) today announced the launch of www.nutraplete.com. Featured on the site is Nutraplete's Immune System Formula Therapeutic Drink Mix that is the first therapeutic dietary supplement designed specifically for people living with HIV/AIDS, created by BioSource Therapeutics, Inc., a GLSN company.
This new Nutraplete web site is designed to educate both patients and healthcare professionals about the unique benefits of its Chocolate-Orange and Wild Summer Berry flavored therapeutic drink mixes, comprised of advanced pharmaceutical-grade supplements. Nutraplete.com is also designed to serve as a resource providing comprehensive information and other support for HIV/AIDS communities including informative newsletters, a learning quiz, and community resources.
Nutraplete's Immune System Formula is a multi-nutritional supplement, designed to address AIDS Wasting Syndrome, which works in conjunction with antiviral therapies and assists patients in the adherence and tolerance of treatments. Nutraplete is a "functional food" that encourages the restoration of lean body mass, can inhibit pro-oxidative stress, and improve immune function. Nutraplete is available by prescription and will soon be included on Medicaid and AIDS Drugs Assistance Program (ADAP) formularies in all 50 states, and is to be distributed by many national and HIV Pharmacies throughout the country. Nutraplete will also soon be available via our online store. Go to www.nutraplete.com for more information on our product and how to get it.
About Galea Life Sciences, Inc.
Galea Life Sciences, Inc. (Pink Sheets:GLSN) is currently a non-reporting over-the-counter publicly traded company. GLSN identifies and acquires new and innovative nutraceutical product and dietary supplement companies with outstanding growth potential. GLSN's focus is in the emerging scientific field of advanced nutritional supplements designed to support traditional medical treatments and therapies.
BioSource Therapeutics, Inc. (BST), a GLSN subsidiary, is an entrepreneurial life sciences company. BST specializes in the formulation, manufacturing, marketing and distribution of innovative dietary supplements that benefit people undergoing medical treatments and therapies.
Certain statements in this release constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast," "project," "intend," "expect" "should," "would," and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (finance or operating) or achievements to differ from future results, performance (financing and operating) or achievements expressed or implied by such forward-looking statements. Statements herein express management's beliefs and expectations regarding future performance and are forward-looking and involve risks and uncertainties, including, but not limited to, the ability to negotiate outstanding prior debts of acquired companies; properly identify acquisition partners; adequately perform due diligence; manage and integrate acquired businesses; react to quarterly fluctuations in results; raise working capital and secure other financing; respond to competition and rapidly changing technology; deal with market and stock price fluctuations; and other risks.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.